한글목차

세계의 내분비 검사 시장은 2024년 28억 1,000만 달러에서 2030년까지 46억 9,000만 달러로, CAGR 8.92%로 성장할 것으로 예측됩니다.

내분비 검사는 체내의 중요한 호르몬 균형을 조절하는 내분비계의 기능을 평가하기 위해 고안된 진단 절차를 말합니다. 이 검사들은 다양한 생체 시료의 호르몬 농도를 측정하여 당뇨병, 갑상선 질환, 부신 기능 부전 등의 상태를 진단하고 모니터링합니다.

주요 시장 촉진요인

내분비 질환의 증가 추세는 진단 솔루션의 수요를 근본적으로 견인하고 있습니다. 갑상선 기능장애, 당뇨병, 부신기능부전 등의 질환은 전 세계적으로 증가 추세에 있으며, 효과적인 관리와 환자의 예후 개선을 위해 정확하고 신속한 진단이 요구되고 있습니다.

주요 시장 과제

고도의 검사 기술에 따른 높은 비용은 세계 내분비 검사 시장의 성장에 큰 장벽이 되고 있습니다. 이러한 재정적 장벽은 특히 의료 예산이 제한된 개발도상국에서 필수 진단 절차의 보급을 직접적으로 제한하고 있습니다.

주요 시장 동향

소비자 직접 검사 서비스의 확대는 중요한 시장 동향으로, 기존 의사의 진단서 없이도 개인이 직접 진단 서비스를 이용할 수 있도록 하고 있습니다. 이러한 패러다임의 변화는 건강 정보에 대한 접근성을 민주화하고, 환자의 건강 증진에 대한 노력을 촉진하며, 건강 관리에 대한 적극적인 태도를 장려하고 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 내분비 검사 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 검사 유형별(에스트라디올(E2) 검사, 난포자극호르몬(FSH) 검사, 인간 융모성 성선자극호르몬(hCG) 호르몬 검사, 황체 형성 호르몬(LH) 검사, 디하이드로에피안드로스테론 황산염(DHEAS) 검사, 프로게스테론 검사, 테스토스테론 검사, 갑상선 자극 호르몬(TSH) 검사, 프로락틴 검사, 코르티솔 검사, 인슐린 검사, 기타)
  • 기술별(텐덤 질량 분석법, 면역측정법, 단클론항체·다클론항체 기술, 센서 기술, 임상화학, 기타)
  • 최종사용자별(병원·진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 내분비 검사 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 내분비 검사 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 내분비 검사 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 내분비 검사 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 내분비 검사 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 내분비 검사 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Abbott Laboratories
• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• AB Sciex
• bioMerieux SA
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Ortho Clinical Diagnostics

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Endocrine Testing Market will grow from USD 2.81 Billion in 2024 to USD 4.69 Billion by 2030 at a 8.92% CAGR. Endocrine testing encompasses diagnostic procedures designed to evaluate the function of the endocrine system, which regulates essential hormonal balance throughout the body. These tests measure hormone levels in various biological samples to diagnose and monitor conditions such as diabetes, thyroid disorders, and adrenal insufficiency.

Key Market Drivers

The rising prevalence of endocrine disorders fundamentally drives the demand for diagnostic solutions. Conditions such as thyroid dysfunction, diabetes, and adrenal insufficiencies are increasingly widespread globally, necessitating accurate and timely identification for effective management and improved patient outcomes. This escalating burden translates directly into a greater need for comprehensive endocrine testing.

Key Market Challenges

The high cost associated with advanced testing technologies represents a significant impediment to the growth of the global endocrine testing market. This financial barrier directly restricts the widespread adoption of essential diagnostic procedures, particularly in developing regions where healthcare budgets are often limited. Smaller healthcare settings globally also face considerable challenges in acquiring and maintaining these expensive platforms, which consequently curtails their capacity to offer a comprehensive range of endocrine tests.

Key Market Trends

The growth of direct-to-consumer endocrine testing offerings is a significant market trend, enabling individuals to directly access diagnostic services without a traditional physician's referral. This paradigm shift democratizes access to health information, empowers patients in their wellness journeys, and fosters a proactive approach to health management. According to the American Diabetes Association's 2024 Annual Report, nearly 1 in 2 Americans has diabetes or prediabetes, collectively representing 136 million Americans living with these conditions.

Key Market Players

• Abbott Laboratories
• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• AB Sciex
• bioMerieux SA
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Ortho Clinical Diagnostics

Report Scope:

In this report, the Global Endocrine Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endocrine Testing Market, By Test Type:

• Estradiol (E2) Test
• Follicle Stimulating Hormone (FSH) Test
• Human Chorionic Gonadotropin (hCG) Hormone Test
• Luteinizing Hormone (LH) Test
• Dehydroepiandrosterone Sulfate (DHEAS) Test
• Progesterone Test
• Testosterone Test
• Thyroid Stimulating Hormone (TSH) Test
• Prolactin Test
• Cortisol Test
• Insulin Test
• Others

Endocrine Testing Market, By Technology:

• Tandem Mass Spectrometry
• Immunoassay
• Monoclonal & Polyclonal Antibody Technologies
• Sensor Technology
• Clinical Chemistry
• Others

Endocrine Testing Market, By End user:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Endocrine Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Endocrine Testing Market.

Available Customizations:

Global Endocrine Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Endocrine Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test, Others)
  • 5.2.2. By Technology (Tandem Mass Spectrometry, Immunoassay, Monoclonal & Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Others)
  • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Endocrine Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Endocrine Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Endocrine Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Endocrine Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By End user

7. Europe Endocrine Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Endocrine Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By End user
  • 7.3.2. France Endocrine Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Endocrine Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Endocrine Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Endocrine Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By End user

8. Asia Pacific Endocrine Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Endocrine Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By End user
  • 8.3.2. India Endocrine Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Endocrine Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Endocrine Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Endocrine Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By End user

9. Middle East & Africa Endocrine Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Endocrine Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Endocrine Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Endocrine Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By End user

10. South America Endocrine Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Endocrine Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Endocrine Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Endocrine Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Endocrine Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. Bio-Rad Laboratories Inc.
• 15.4. AB Sciex
• 15.5. bioMerieux SA
• 15.6. DiaSorin S.p.A.
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Laboratory Corporation of America Holdings
• 15.9. Quest Diagnostics Incorporated
• 15.10. Ortho Clinical Diagnostics

16. Strategic Recommendations

17. About Us & Disclaimer